Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · FibroBiologics, Inc. (FBLG)

FibroBiologics enters $1.2 million convertible debenture deal with Peak One

Negative Impact 3 of 5 financing Written later

FibroBiologics sold Peak One Opportunity Fund a $1.2 million convertible debenture for $1,020,000, a 15% original issue discount, and issued 125,000 restricted commitment shares. The debenture matures October 8, 2027, and is convertible only after an Event of Default, at a fixed $0.78 per share. Shareholders face possible dilution and near-term repayment obligations, with the company's interim payments of $1,080,000 due in April 2027.

Key points

  • Debenture principal of $1,200,000 sold for $1,020,000, with 0% interest and a maturity date of October 8, 2027
  • Interim payments of $1,080,000 due April 8, 2027, and $60,000 due July 8, 2027, with the balance at maturity
  • Conversion only after an Event of Default, at $0.78 per share; issuance capped at 1,671,094 shares absent stockholder approval
  • Company issued 125,000 commitment shares and paid a $20,000 non-accountable fee to Peak One

The filing

CompanyFibroBiologics, Inc. (FBLG)
Form8-K, current report
Filed with the SECOct 8, 2026, 5:15 PM ET
Accession number0001193125-26-418065

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.